Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Aims/hypothesis: Intra-abdominal or visceral obesity is associated with insulin resistance and an increased risk for cardiovascular disease. This study aimed to compare the effects of semaglutide 1.0 mg and canagliflozin 300 mg on body composition in a subset of participants from the SUSTAIN 8 Phase IIIB, randomised double-blind trial who underwent whole-body dual-energy x-ray absorptiometry (DXA) scanning. Methods: Adults (age ≥18 years) with type 2 diabetes, HbA 1c 53–91 mmol/mol (7.0–10.5%), on a stable daily dose of metformin (≥1500 mg or maximum tolerated dose) and with an eGFR ≥60 ml min −1 [1.73 m] −2 were randomised 1:1 to semaglutide 1.0 mg once weekly and canagliflozin placebo once daily, or canagliflozin 300 mg once daily and semaglutide placebo once weekly. Body composition was assessed using whole-body DXA scans. The study participants and investigator remained blinded throughout the trial, and quality of DXA scans was evaluated in a blinded manner. Change from baseline to week 52 in total fat mass (kg) was the confirmatory efficacy endpoint. Results: A subset of 178 participants (semaglutide, n = 88; canagliflozin, n = 90) underwent DXA scanning at screening and were randomised into the substudy. Of these, 114 (semaglutide, n = 53; canagliflozin, n = 61) participants had observed end-of-treatment data included in the confirmatory efficacy analysis. Of the 178 participants in the substudy, numerical improvements in body composition (including fat mass, lean mass and visceral fat mass) were observed after 52 weeks with both treatments. Total fat mass (baseline 33.2 kg) was reduced by 3.4 kg and 2.6 kg with semaglutide and canagliflozin, respectively (estimated treatment difference: –0.79 [95% CI −2.10, 0.51]). Although total lean mass (baseline 51.3 kg) was also reduced by 2.3 kg and 1.5 kg with semaglutide and canagliflozin, respectively (estimated treatment difference: −0.78 [−1.61, 0.04]), the proportion of lean mass (baseline 59.4%) increased by 1.2%- and 1.1%-point, respectively (estimated treatment difference 0.14 [−0.89, 1.17]). Changes in visceral fat mass and overall changes in body composition (assessed by the fat to lean mass ratio) were comparable between the two treatment groups. Conclusions/interpretation: In individuals with uncontrolled type 2 diabetes on stable-dose metformin therapy, the changes in body composition with semaglutide and canagliflozin were not significantly different. Although numerical improvements in body composition were observed following treatment in both treatment arms, the specific impact of both treatments on body composition in the absence of a placebo arm is speculative at this stage. Trial registration: ClinicalTrials.gov NCT03136484. Funding: This trial was supported by Novo Nordisk A/S, Denmark.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 3 Body composition outcomes after 52 weeks of treatment. Change from baseline in total fat mass: kg (a) and % (b); total lean mass: kg (c) and % (d); visceral fat mass: kg (e) and % (f); ratio of total fat mass to total lean mass (g); and cumulative change in total fat mass (h). ‘On-treatment without rescue medication’ data ( n =114 [semaglutide, n = 53; canagliflozin, n = 61]). Missing data were multiple imputed using observed data from participants within the same group defined by randomised treatment, using a regression model including region as categorical effect and data from baseline as covariate. (a–g) Responses were analysed using an ANCOVA with treatment and region as fixed factors and baseline value as covariate. Regions were defined as North America (USA and Canada); Region Europe (UK, Ireland and Sweden); or International Operations (Lebanon, Malaysia, Argentina, Mexico, Brazil and India). Numbers on the bars may not match the numbers on the scale due to rounding. (h) The dashed line on the y-axis shows the 50th percentile, while the dashed line on the x-axis shows the reference value for no change](https://figures.cochat.ai/paper-figures/69a4c2a55a7c458893357ada1b2af7f7/effects-of-once-weekly-semaglutide-vs-once-daily-canagliflozin-on-body-figure-3.jpg)
![Fig. 4 Correlation of absolute change in total fat mass (kg) with change in body weight (a), HbA1c (b), SBP (c) and DBP (d) after 52 weeks of treatment. Each point represents data (observed or imputed) from one participant. ‘On-treatment without rescue medication’ data for all randomised participants (n = 178 [semaglutide, n = 88; canagliflozin, n = 90]). Missing data were multiple imputed using data from participants within the same group defined by randomised treatment. Data are plotted for the first ten out of 500 imputations. DBP, diastolic BP; SBP, systolic BP](https://figures.cochat.ai/paper-figures/b4a655c2b16e47b094473a657007b1c3/effects-of-once-weekly-semaglutide-vs-once-daily-canagliflozin-on-body-figure-4.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of the total weight loss with semaglutide approximately 45% was lean mass and for tirzepatide it was 25.7%.”
From New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? (2025) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, in the SUSTAIN-8 sub study, patients treated with semaglutide lost 2.3 kg (−4.5%) of lean mass out of a total 5.3 kg (−6.0%) weight loss, equating to 43.4%, although lean mass as a proportion of total body mass increased slightly [30].”
From Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes (2025) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“resulting in 43.4% of weight loss attributable to lean mass”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [111]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“while the ratio of lean mass to total mass increased by 1.2% from the baseline [111].”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [111]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Data are very limited for the highest dose of Semaglutide (2.4 mg), as most studies have focused on the 1 mg dose. 8 , 9 , 10 , 11”
From Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study (2026) · cites this paper as [8]
Experimental — accuracy not yet measured
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“The efficacy and safety of once-weekly semaglutide have been established in the SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2Diabetes) clinical trial programme across the continuumof care in individuals with type 2 diabetes vs placebo and a range of comparators (SUSTAIN 1–5 and 7–10) [11–19] and…”
BackgroundSelf-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 1×
“The efficacy and safety of canagliflozin 100 mg and 300 mg have been demonstrated in an extensive clinical development programme that included cardiovascular and renal outcomes trials (CANVAS, CANVAS-R and CREDENCE) [22, 23].”
BackgroundHubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Mechanisms linking obesity with cardiovascular disease
Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006) · Nature · doi:10.1038/nature05487 · Cited by 2,814 · cited 1×
“Abdominal obesity is a key factor in the development of diabetes and cardiovascular disease [30] and is a risk factor for several chronic diseases with cardiometabolic homeostasis [31].”
BackgroundAssociation between insulin resistance and the development of cardiovascular disease
Ormazabal, V., Nair, S., Elfeky, O., Aguayo, C., Salomon, C., & Zuñiga, F. A. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0762-4 · Cited by 2,280 · cited 1×
“Intra-abdominal or visceral obesity in particular is associatedwith insulin resistance [3, 4] and an increased risk for developing cardiovascular disease [4, 5].”
BackgroundSkeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
DeFronzo, R. A., & Tripathy, D. (2009) · Diabetes Care · doi:10.2337/dc09-s302 · Cited by 2,102
Statistical Analysis with Missing Data
Bo., N., Little, R. J. A., & Rubin, D. B. (1988) · Population (French Edition) · doi:10.2307/1533221 · Cited by 2,095
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455 · cited 1×
“In addition to providing recommendations for achieving glycaemic control, current type 2 diabetes guidelines emphasise the importance of weight loss through lifestyle changes, surgical interventions or medications [6, 7].”
BackgroundBolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867 · cited 1×
“Thus, the caloric loss from glucosuria, and not fluid loss, was responsible for the reductions [38].”
BackgroundPratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Self-citationSorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Assessment methods in human body composition
Lee, S. Y., & Gallagher, D. (2008) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32830b5f23 · Cited by 694
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Self-citationLean Tissue Imaging: A New Era for Nutritional Assessment and Intervention
Prado, C. M. M., & Heymsfield, S. B. (2014) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607114550189 · Cited by 550 · cited 2×
“However, body thickness and hydration status can affect results [49], and lean muscle mass may also include non-muscle components, such as blood or interstitial fluid, leading to measurement error [50].”
BackgroundAhrén, B., Masmiquel, L., Kumar, H., Sargin, M., Karsbøl, J. D., Jacobsen, S. H., & Chow, F. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30092-x · Cited by 495
Aroda, V. R., Bain, S. C., Cariou, B., Piletič, M., Rose, L., Axelsen, M., Rowe, E., & DeVries, J. H. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30085-2 · Cited by 464
Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial.
Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P.-L., Wijayasinghe, N., & Norwood, P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00070 · Cited by 412
Self-citationCapehorn, M. S., Catarig, A.-M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., Vergès, B., & Marre, M. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.101117 · Cited by 412
Self-citationZinman, B., Bhosekar, V., Busch, R., Holst, I., Ludvik, B., Thielke, D., Thrasher, J., Woo, V., & Philis-Tsimikas, A. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30066-x · Cited by 376
Self-citationMeasurement of muscle mass in sarcopenia: from imaging to biochemical markers
Tosato, M., Marzetti, E., Cesari, M., Savera, G., Miller, R. R., Bernabei, R., Landi, F., & Calvani, R. (2017) · Aging Clinical and Experimental Research · doi:10.1007/s40520-016-0717-0 · Cited by 320 · cited 1×
“In addition, analysis and quality assessments of the DXA scans were performed by one central imaging laboratory using one brand of scanner, reducing the likelihood of inconsistencies in bone and soft-tissue measurements that can occur due to variability of hardware and software packages between DXA equipment manufactu…”
MethodJendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M., Zdravkovic, M., Strauss, B. J., Garber, A. J., & Groups, O. B. O. T. L. A. L. S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01158.x · Cited by 312 · cited 5×
“While indirect comparisons across clinical trials should be interpreted with caution, given the heterogeneity of the study populations, these findings suggest that body composition changes with semaglutide are consistent with those in previous studies of other GLP-1RAs.”
BackgroundResultInfluentialLingvay, I., Catarig, A.-M., Frias, J. P., Kumar, H., Lausvig, N. L., le Roux, C. W., Thielke, D., Viljoen, A., & McCrimmon, R. J. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30311-0 · Cited by 298 · cited 3×
“NCT03136484) has been described previously [17].”
BackgroundInfluentialSelf-citationObesity, insulin resistance and comorbidities? Mechanisms of association
Castro, A. V. B., Kolka, C. M., Kim, S. P., & Bergman, R. N. (2014) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/0004-2730000003223 · Cited by 254 · cited 1×
“Intra-abdominal or visceral obesity in particular is associatedwith insulin resistance [3, 4] and an increased risk for developing cardiovascular disease [4, 5].”
BackgroundSchork, A., Saynisch, J., Vosseler, A., Jaghutriz, B. A., Heyne, N., Peter, A., Häring, H.-U., Stefan, N., Fritsche, A., & Artunc, F. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0852-y · Cited by 227 · cited 1×
“This is supported by results from a small study finding that changes in extracellular water volume with SGLT-2is are transient, and not responsible for long-term weight loss with this drug class [39].”
ResultBrown, E., Wilding, J. P. H., Barber, T. M., Alam, U., & Cuthbertson, D. J. (2019) · Obesity Reviews · doi:10.1111/obr.12841 · Cited by 222 · cited 1×
“These changes are supported by the proposed mechanisms of weight loss with GLP-1RAs through appetite modulation via the central nervous system with minimal effect on energy expenditure [42, 43], as well as through the increase of natriuresis caused by inhibition of the sodium–hydrogen ion transporter in the proximal t…”
BackgroundWeight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
Van Gaal, L., & Scheen, A. (2015) · Diabetes Care · doi:10.2337/dc14-1630 · Cited by 221 · cited 4×
“Although many conventional glucose-lowering therapies may contribute to weight gain, treatment with GLP-1RAs and SGLT-2is has been associated with clinically meaningful weight loss [2].”
BackgroundInfluentialBodyweight Changes Associated with Antihyperglycaemic Agents in Type 2 Diabetes Mellitus
Hermansen, K., & Mortensen, L. S. (2007) · Drug Safety · doi:10.2165/00002018-200730120-00005 · Cited by 174 · cited 1×
“The positive effects of both treatments on weight loss demonstrated previously [11–20, 24] highlight the importance of newer agents among current pharmacological options, compared with older, standard approaches for type 2 diabetes that may increase or have little effect on weight [46].”
BackgroundBretz, F., Posch, M., Glimm, E., Klinglmueller, F., Maurer, W., & Rohmeyer, K. (2011) · Biometrical Journal · doi:10.1002/bimj.201000239 · Cited by 172
Effects of Weight Loss on Lean Mass, Strength, Bone, and Aerobic Capacity
WEISS, E. P., JORDAN, R. C., FRESE, E. M., ALBERT, S. G., & VILLAREAL, D. T. (2017) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000001074 · Cited by 169 · cited 1×
“However, body thickness and hydration status can affect results [49], and lean muscle mass may also include non-muscle components, such as blood or interstitial fluid, leading to measurement error [50].”
BackgroundAmerican Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s008 · Cited by 149
Perna, S., Guido, D., Bologna, C., Solerte, S. B., Guerriero, F., Isu, A., & Rondanelli, M. (2016) · Aging Clinical and Experimental Research · doi:10.1007/s40520-015-0525-y · Cited by 125 · cited 5×
“While indirect comparisons across clinical trials should be interpreted with caution, given the heterogeneity of the study populations, these findings suggest that body composition changes with semaglutide are consistent with those in previous studies of other GLP-1RAs.”
BackgroundResultInfluentialGLP ‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
Ryan, D., & Acosta, A. (2015) · Obesity · doi:10.1002/oby.21107 · Cited by 112
Weight management in older adults
Gill, L. E., Bartels, S. J., & Batsis, J. A. (2015) · Current Obesity Reports · doi:10.1007/s13679-015-0161-z · Cited by 109 · cited 1×
“induced weight loss is associated with corresponding changes in both body fat and fat-free mass, including muscle [33].”
BackgroundPi-Sunyer, F. X. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.09.2056 · Cited by 86 · cited 1×
“This is an important feature, because weight gain can lead to non-compliance with therapy [8].”
BackgroundMeasuring body composition in overweight individuals by dual energy x-ray absorptiometry
Brownbill, R. A., & Ilich, J. Z. (2005) · BMC Medical Imaging · doi:10.1186/1471-2342-5-1 · Cited by 79 · cited 2×
“DXA, a two-compartment method of body composition analysis that separates body components into fat mass and fat-free mass, is one of the most popular and widely used non-invasive techniques for estimating whole-body and regional body composition [29].”
BackgroundMethodBlonde, L., Stenlöf, K., Fung, A., Xie, J., Canovatchel, W., & Meininger, G. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1169894 · Cited by 71
Sarin, H. V., Lee, J. H., Jauhiainen, M., Joensuu, A., Borodulin, K., Männistö, S., Jin, Z., Terwilliger, J. D., Isola, V., Ahtiainen, J. P., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40107-6 · Cited by 67 · cited 2×
“Abdominal obesity is a key factor in the development of diabetes and cardiovascular disease [30] and is a risk factor for several chronic diseases with cardiometabolic homeostasis [31].”
BackgroundSeufert, J. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s90662 · Cited by 65
Ohta, A., Kato, H., Ishii, S., Sasaki, Y., Nakamura, Y., Nakagawa, T., Nagai, Y., & Tanaka, Y. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1363888 · Cited by 56 · cited 1×
“6 kg loss in appendicular lean mass (a good marker of skeletal muscle mass), suggesting that SGLT-2is may induce catabolism of both body fat and muscle secondary to glycosuria [36].”
BackgroundCanagliflozin review – safety and efficacy profile in patients with T2DM
Jakher, H., Chang, T. I., Tan, M., & Mahaffey, K. W. (2019) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s184437 · Cited by 48 · cited 1×
“The efficacy and safety of canagliflozin 100 mg and 300 mg have been demonstrated in an extensive clinical development programme that included cardiovascular and renal outcomes trials (CANVAS, CANVAS-R and CREDENCE) [22, 23].”
BackgroundIshii, S., Nagai, Y., Sada, Y., Fukuda, H., Nakamura, Y., Matsuba, R., Nakagawa, T., Kato, H., & Tanaka, Y. (2019) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3647 · Cited by 41 · cited 8×
“While indirect comparisons across clinical trials should be interpreted with caution, given the heterogeneity of the study populations, these findings suggest that body composition changes with semaglutide are consistent with those in previous studies of other GLP-1RAs.”
BackgroundResultInfluentialKim, B., Tsujimoto, T., So, R., Zhao, X., Oh, S., & Tanaka, K. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s132707 · Cited by 32 · cited 1×
“In individuals with type 2 diabetes, it is preferable to reduce fat without significant loss of lean mass [32], although this can occur during weight loss in those who are obese [34].”
BackgroundBaretić, M., Kušec, V., & Pavlić-Renar, I. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0517-y · Cited by 12 · cited 1×
“These changes are supported by the proposed mechanisms of weight loss with GLP-1RAs through appetite modulation via the central nervous system with minimal effect on energy expenditure [42, 43], as well as through the increase of natriuresis caused by inhibition of the sodium–hydrogen ion transporter in the proximal t…”
BackgroundNauck, M. A., de la Rosa, R., Marre, M., Woo, V., Hansen, T. K., Larsen, J. R., Yildirim, E., & Wilding, J. P. H. (2019) · Diabetologie und Stoffwechsel · doi:10.1055/s-0039-1688353 · Cited by 1
Research works printed but not linked: 1
- International Conference on Harmonisation–World Health Organization Guideline for Good Clinical Practice (1996) ICH harmonised tripartite guideline good clinical practice. Available from https://apps.who.int/medicinedocs/en/m/abstract/Js22154en/. Accessed 25 November 2019
Cited by
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
“0 mg) in persons with obesity(22) and in those with type 2 diabetes.(33) The weight loss and improvements with respect to cardiometabolic risk factors with semaglutide reported here will be complemented by an ongoing cardiovascular outcomes trial in participants with overweight or obesity and established cardiovascula…”
BackgroundSelf-citationObesity Phenotypes, Diabetes, and Cardiovascular Diseases
Piché, M.-E., Tchernof, A., & Després, J.-P. (2020) · Circulation Research · doi:10.1161/circresaha.120.316101 · Cited by 1,986
Changes in lean body mass with glucagon‐like peptide ‐1‐based therapies and mitigation strategies
Neeland, I. J., Linge, J., & Birkenfeld, A. L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15728 · Cited by 391
“31 In contrast to these findings, a study comparing semaglutide 1 mg and tirzepatide with placebo in patients with type 2 diabetes showed lean mass reductions of approximately 15% or less of total weight loss across all groups.”
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
Karakasis, P., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156113 · Cited by 242
Metadata
- Authors
- McCrimmon, R. J., Catarig, A.-M., Frias, J. P., Lausvig, N. L., le Roux, C. W., Thielke, D., & Lingvay, I.
- Affiliations
- University of Dundee (GB)
- Novo Nordisk (Denmark) (DK)
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- McCrimmon, Rory J.
- Venue
- Diabetologia
- Published
- 2020-01-02
- Volume
- 63
- Issue
- 3
- Pages
- 473-485
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC6997246
- OpenAlex
- W2997634477
- Semantic Scholar
- 1f6f822362842f16632d7a52eb488e033bfdcd11
- Cited by
- 184
- References
- 48
- Citations by year
- 2026: 56 · 2025: 61 · 2024: 30 · 2023: 20 · 2022: 7 · 2021: 6 · 2020: 3
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Diabetologia (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion, cc-by)
- Lenus, The Irish Health Repository (Dr Steevens Hospital Library) (submittedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, canagliflozin, type 2 diabetes, body composition, fat mass, lean body mass, visceral fat, GLP-1 receptor agonists, SGLT2 inhibitors, dual-energy X-ray absorptiometry, insulin resistance, cardiovascular risk, weight loss
- MeSH terms
- Canagliflozin, Semaglutide, Aged, Blood Glucose, Body Composition, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Administration Routes, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Male, Metformin, Middle Aged, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.